SG Americas Securities
CRVS icon

SG Americas Securities’s Corvus Pharmaceuticals CRVS Stock Holding History

SG Americas Securities’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$463K Sell
30,994
-4,426
-12% -$61.4K ﹤0.01% 2363
2026
Q1 		$518K Buy
35,420
+15,399
+77% +$246K ﹤0.01% 2164
2025
Q4 		$154K Buy
+20,021
New +$158K ﹤0.01% 3034
2018
Q1 		– Sell
-14,438
Closed -$150K – 3287
2017
Q4 		$150K Buy
+14,438
New +$185K ﹤0.01% 2631

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

SG Americas Securities's CRVS Position: Q2 2026 in Review

SG Americas Securities reduced its Corvus Pharmaceuticals (CRVS) stake by 12% in Q2 2026, selling an estimated $61.4K and leaving 30,994 shares worth $463K. The position accounts for ﹤0.01% of the portfolio, ranked #2363.

SG Americas Securities first reported a position in CRVS in Q4 2017 and has held it in 4 quarters since. The position peaked at $518K in Q1 2026. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • SG Americas Securities held 30,994 shares of Corvus Pharmaceuticals worth $463K as of Q2 2026.
  • SG Americas Securities sold 4,426 Corvus Pharmaceuticals shares in Q2 2026, an estimated $61.4K.
  • Corvus Pharmaceuticals made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #2363 holding.
  • SG Americas Securities first reported a position in Corvus Pharmaceuticals in Q4 2017 and has held it in 4 quarters since.
  • SG Americas Securities's Corvus Pharmaceuticals position peaked at $518K in Q1 2026.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.